Lung Cancer

Tecemotide (INN; emepepimut-S (USAN); formerly known as BLP25 or EMD 531444) is a synthetic lipopeptide that is used as antigen in an investigational therapeutic cancer vaccine (formerly known as Stimuvax, L-BLP25, BLP25 liposomal vaccine, or BLP25 liposome vaccine).

Read more in the app

New study challenges “obesity paradox” in lung cancer, points to suppressed airway immunity

Cigarette smoke may prime lung stem cells for different types of lung cancer

Scientists just found a way to fight lung cancer and muscle wasting at the same time

UCLA research team awarded $1 million to develop new approach for detecting lung cancer

Can your breath help diagnose lung cancer?

Scientists identify rare genetic mutation that dramatically raises risk of lung cancer in nonsmokers

Georgetown investigator presents final PAPILLON trial results showing long-term survival in a subset of lung cancer

AI tool successfully predicts outcomes of immunotherapy in lung cancer

Vitamin B2 and Tumor Bacteria May Unlock a New Way To Fight Lung Cancer

Scientists Discover Hidden Cells That Help Lung Cancer Evade the Immune System

Patients diagnosed with lung cancer found to have more microplastic in their lungs

Biomarkers that predict improved outcomes after perioperative immune-based therapy for lung cancer

Landmark pancreatic cancer drug shows potential against lung cancer too

Multi-source data-driven machine learning reshapes the diagnosis and treatment of lung cancer

Drug that targets an inflammatory enzyme could help prevent lung cancer - EurekAlert!

RNA-based testing uncovers extraordinary diversity in mutations driving lung cancer - EurekAlert!

Screening eligibility and survival among patients with lung cancer in Korea - EurekAlert!

Years After He Quit Smoking, a Lung Cancer Scan Saved His Life

Why are healthy young non-smokers developing lung cancer?